Navigation Links
Micromet Announces Public Offering of Common Stock
Date:7/29/2009

are currently in clinical trials. Its BiTE antibody blinatumomab (MT103) is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia (ALL), and in a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma (NHL). A second BiTE antibody, MT110, is in a phase 1 clinical trial for the treatment of patients with solid tumors. MT110 binds to the epithelial cell adhesion molecule, or EpCAM, which is overexpressed in many solid tumors. Micromet's human monoclonal antibody adecatumumab (MT201) also binds to EpCAM and is being developed under a collaboration with Merck Serono. Adecatumomab is in a phase 2 clinical trial in colorectal carcinoma patients after complete resection of liver metastases, and a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. Micromet's monoclonal antibody MT293, also known as TRC093, is licensed to TRACON Pharmaceuticals, Inc., and is in a phase 1 clinical trial for the treatment of patients with cancer. MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis, is in a phase 1 clinical trial conducted by Micromet's collaboration partner Nycomed. Micromet's licensee Morphotek, a wholly-owned subsidiary of Eisai, is also expected to initiate a phase 1 clinical trial in 2009 with Micromet's glycolipid-binding human antibody MT228 for the treatment of melanoma.

Micromet's preclinical product pipeline includes several novel BiTE antibodies generated with its proprietary BiTE antibody platform technology. A BiTE antibody targeting CEA for the treatment of solid tumors is being developed in collaboration with MedImmune. In addition, Micromet has entered into an option,
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Micromet, Inc. to Host Conference Call and Webcast to Report Second Quarter 2009 Financial Results on August 6, 2009
2. Micromet Added to Russell 3000 Index
3. Micromet to Host Conference Call and Webcast to Discuss Blinatumomab Data Presented at EHA on June 8, 2009
4. Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel
5. Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO
6. Micromet, Inc. to Host Conference Call and Webcast to Report First Quarter 2009 Financial Results on May 6, 2009
7. Micromet Presents Data at AACR Meeting Showing Elimination of Colorectal Cancer Stem Cells by BiTE Antibody MT110
8. Micromet to Present at the Future Leaders in the Biotech Industry Conference on April 2, 2009
9. Micromet Adds Sir Walter Bodmer and Bernard Fox to Its Advisory Panel for BiTE Antibody Therapeutics
10. Micromet to Present Six Posters on Progress of BiTE Antibodies at the Annual Meeting of American Association for Cancer Research
11. Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... SoundConnect , an award ... proud to announce the strategic additions of implementation, ... Boston, Charleston and Atlanta offices. SoundConnect’s organizational ... for hosted solutions, collaboration and mobility that improve ... , SoundConnect was founded in 2004, with the ...
(Date:7/29/2014)... number of significant technological challenges in their quest ... created for the James Webb Space Telescope. , ... a scientist at NASA,s Goddard Space Flight Center ... microshutter arrays that is, those activated by ... as the current technology,s magnetically activated arrays. This ...
(Date:7/29/2014)... 29, 2014   Sequenom, Inc. (NASDAQ: ... innovative genetic analysis solutions, and Mayo Medical Laboratories ... in the United States , have ... and applications. "We have great appreciation for ... and we welcome the opportunity to partner with the ...
(Date:7/29/2014)... Quantum Cheshire Cat: Can a particle be separated from ... Nature Communications , published the results of the first ... field, conducted by Chapman University in Orange, CA, and ... seen a cat without a grin," thought Alice in ... most curious thing I ever saw in my life!" ...
Breaking Biology Technology:SoundConnect Organization and Culture is Evolving 2Revolutionary microshutter technology hurdles significant challenges 2Revolutionary microshutter technology hurdles significant challenges 3Revolutionary microshutter technology hurdles significant challenges 4Sequenom Enters Into License Agreement With Mayo Medical Laboratories 2Sequenom Enters Into License Agreement With Mayo Medical Laboratories 3Sequenom Enters Into License Agreement With Mayo Medical Laboratories 4The quantum Cheshire cat: Scientists separate a particle from its properties 2The quantum Cheshire cat: Scientists separate a particle from its properties 3The quantum Cheshire cat: Scientists separate a particle from its properties 4
... Enlarge and Worsen Over Time , , CHICAGO, June 15 ... enlarged leg veins as a cosmetic issue without recognizing they can ... their doctors for other health symptoms, Vein Clinics of America is ... from affecting their everyday routine. , , To view the ...
... 15 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ... appointment of Scott Peterson, Ph.D., as Vice President, ... Dr. Peterson will be responsible for overseeing those ... will support the advancement of the Company,s pipeline ...
... June 15 Congressional Quarterly presents a 360-degree look ... follow-on versions of biotech drugs. This CQ Forum will ... groups, and leading researchers regarding the complex structures of ... Will the availability of these products save money for ...
Cached Biology Technology:Video: Varicose Veins, Much More Than a Cosmetic Issue, Can Prove a Health Risk 2Video: Varicose Veins, Much More Than a Cosmetic Issue, Can Prove a Health Risk 3Video: Varicose Veins, Much More Than a Cosmetic Issue, Can Prove a Health Risk 4Oncothyreon appoints Scott Peterson as Vice President of Research and Development 2Oncothyreon appoints Scott Peterson as Vice President of Research and Development 3
(Date:7/30/2014)... is a subject of major interest in neuroscience. ... during the distinct stages of Wallerian degeneration: transcription ... dedifferentiation. Although gene expression responses in the distal ... injury are known, differences in gene expression between ... Dengbing Yao and co-workers from Nantong University, China ...
(Date:7/30/2014)... multitude of cells types. Researchers would like to understand how ... cells that make up the organs and other structures of ... chains of sugars that dangle from proteins on surfaces of ... San Diego, has created synthetic molecules that can stand in ... to direct the process, they report in the Journal ...
(Date:7/30/2014)... scientists unveiled the first high-resolution map of the ... country of Per. The new and improved methodology ... change for future market-based carbon economies. The ... ecological diversity and it provides the critical input ... conservation, land use, and enforcement purposes. The technique ...
Breaking Biology News(10 mins):Peru's carbon quantified: Economic and conservation boon 2Peru's carbon quantified: Economic and conservation boon 3
... to John Ellis for his pioneering contributions to biochemistry, ... Professor in the Department of Biological Sciences at the ... of the Springer book How Science Works: Evolution. Dr. ... London, and completed postdoctoral studies at Oxford University. In ...
... centuries-old religious ceremony of an indigenous people in southern Mexico ... of fish, according to researchers from Texas A&M University. ... World, the Zoque people of southern Mexico would venture each ... Cueva del Azufre to implore their deities for a bountiful ...
... most frustrating problems faced by doctors who treat pancreatic cancer ... 38,000 people in the United States die of the disease ... For almost three decades, scientists and physicians have known ... virtually all pancreatic cancers, making it an important target for ...
Cached Biology News:Moved by religion: Mexican cavefish develop resistance to toxin 2Moved by religion: Mexican cavefish develop resistance to toxin 3UNC team discovers promising target for new pancreatic cancer treatments 2
... >95%NEN Radiolabeled Ligands\n\nReceptor-related research has long been ... radiolabeled ligands selected to keep pace with ... of products and services for receptor research ... radioligands. If you do not find exactly ...
... Software reads and processes raw ... microarray data for analysis. ... one 2-year license for Feature ... , * one CD-ROM ...
Anti-WT-1 Liquid. In 10 μM PBS, 0.2 % BSA, pH 7.6. Recognizes the ~47-55 kDa Wilm's tumor protein in Wilm's tumor tissue. ...
... optimized for siRNA applications, contains magnetic nanoparticles ... nucleic acid of interest. Exploiting magnetic force ... rapidly drawn towards and delivered into the ... Reagent can be used for adherent cells; ...
Biology Products: